Related Experiment Video
Updated: Aug 22, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Targeting the integrated stress response in hematologic malignancies
Gus O Nwosu1, Jason A Powell2,3, Stuart M Pitson4,5,6
1Centre for Cancer Biology, University of South Australia and SA Pathology, UniSA Bradley Building, North Tce, Adelaide, SA, 5001, Australia.
Abstract:
While numerous targeted therapies have been recently adopted to improve the treatment of hematologic malignancies, acquired or intrinsic resistance poses a significant obstacle to their efficacy. Thus, there is increasing need to identify novel, targetable pathways to further improve therapy for these diseases. The integrated stress response is a signaling pathway activated in cancer cells in response to both dysregulated growth and metabolism, and also following exposure to many therapies that appears one such targetable pathway for improved treatment of these diseases. In this review, we discuss the role of the integrated stress response in the biology of hematologic malignancies, its critical involvement in the mechanism of action of targeted therapies, and as a target for pharmacologic modulation as a novel strategy for the treatment of hematologic malignancies.
Insights
Targeted therapies for blood cancers face resistance. The integrated stress response (ISR) pathway is a promising new target for overcoming this resistance and improving cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies are vital for hematologic malignancies but face significant resistance.
- Acquired or intrinsic resistance limits the effectiveness of current treatments.
- Novel therapeutic targets are needed to improve patient outcomes.
Purpose of the Study:
- To review the role of the integrated stress response (ISR) in hematologic malignancies.
- To explore the ISR's involvement in targeted therapy mechanisms.
- To highlight the ISR as a target for novel therapeutic strategies.
Main Methods:
- Literature review of the integrated stress response in hematologic cancers.
- Analysis of ISR's role in targeted therapy resistance.
- Discussion of pharmacologic modulation of the ISR.
Main Results:
- The ISR is activated in cancer cells due to dysregulated growth, metabolism, and therapy exposure.
- The ISR plays a critical role in the efficacy and resistance of targeted therapies.
- Pharmacologic targeting of the ISR presents a novel strategy.
Conclusions:
- The integrated stress response is a key pathway in hematologic malignancies.
- Modulating the ISR can overcome resistance to targeted therapies.
- Targeting the ISR offers a promising avenue for improved hematologic cancer treatment.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Targeted Cancer Therapies
There are several types of targeted therapies against...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Hypothalamic-Pituitary Axis
Hematopoiesis
Psychoneuroimmunology: Diabetes and Cancer

